Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
BMJ Open|October 30, 2012
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesotheliomaGeorge B Carey, Stephanie Kazantsev, Mosmi Surati, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 16, 2026
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9<sup>th</sup> Edition Staging DatabaseSoo-Ryum Yang, Melissa Y Tjota, Emily Goren, et al.
Pharmacogenetics and Genomics|March 20, 2019
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)Federico Innocenti, Chen Jiang, Alexander B Sibley, et al.
International Journal of Cancer|September 16, 2021
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2020
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid TumorsRaffit Hassan, George R Blumenschein, Kathleen N Moore, et al.
Cancer Research|January 7, 2006
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesotheliomaRamasamy Jagadeeswaran, Patrick C Ma, Tanguy Y Seiwert, et al.
The Lancet. Oncology|July 22, 2017
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trialMichele Maio, Arnaud Scherpereel, Luana Calabrò, et al.
The Annals of Thoracic Surgery|April 22, 2026
The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural MesotheliomaJeffrey B Velotta, Anja C Roden, Jonathan Rice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2022
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L Kindler, Pascal Hammel, Michele Reni, et al.
Pageof 16